CDH17 and neoplasm: Additionally, the anti-tumor activity of CDH17-CAR-NK cells is synergistically enhanced by CD47–signal regulatory protein α (SIRPα) axis inhibitor CV1, likely through augmented macrophages activation and an increase in M1-phenotype macrophages in the tumor microenvironment.